节点文献
吡格列酮对糖耐量受损患者的干预治疗研究
Intervention study on effects of pioglitazone on patients with impaired glucose tolerance
【摘要】 目的比较糖耐量受损(IGT)人群药物干预与非药物干预对糖尿病发病率的作用,观察吡格列酮对糖耐量受损IGT干预治疗的疗效。方法200例住院或门诊经口服75克葡萄糖耐量试验OGTT筛查证实为IGT的病人,分成对照组、饮食加运动组、阿卡波糖组、二甲双胍组和吡格列酮组,进行1年干预治疗研究。结果初访时5组基线资料无统计学差异,1年后,对照组空腹血糖FPG无变化,OGTT后2小时血糖2hPG轻度升高,每年糖尿病发病率为12.0%;饮食加运动组FPG及2hPG轻度下降,每年糖尿病的发病率为10.0%,阿卡波糖组、二甲双胍组和吡格列酮组FPG及2hPG均有显著下降,每年糖尿病发病率分别为4.3%、2.2%和2.0%。药物组1年末平均FPG与对照组、饮食加运动组比较差异有显著性。吡格列酮组改善胰岛素敏感指数与其余4组相比差异有显著性意义。结论在IGT干预治疗中,药物干预治疗可达到显著地减少糖尿病发生的效果。吡格列酮在IGT干预治疗中剂量小,胰岛素敏感性增强优于其他药物。
【Abstract】 Objective To observe the effect of drug intervention and non-drug intervention on diabetes mellitus(DM) morbidity in patients with impaired glucose tolerance(IGT). To evaluate the intervention effect of Pioglitazone on the IGT population from becoming diabetes mellitus: Methods 200 patients with IGT diagnosed by orally glucose tolerance test (OGTT) were randomly divided into 5 groups: received therapy with placebo (control group), alimentary control & exercise, Acarbose, Metformin or Pioglitazone respectively. The data were assayed after 1-year intervention treatment. Results The baseline data wasn’t significant diversity befor treatment, after one year there was no changer in fasting plasma glucose (FPG), slight increase in 2h-plasma glucose after OGTT and 12% DM morbidity in control group; light decrease in both FPG and 2h-PG, 10% DM morbidity in alimentary control & exercise group; while overt decrease in both FPG and 2h-PG in Acrbose, Metformin or Pioglitazone group(P<0.05), and 4.3%, 2.2%,2.0%DM morbidity respectively. There was significant decrease in average FPG in drug group, increase in insulin sensitivity index (ISI) in Pioglitazone group, compared with other group on 1 year-end(P<0.05). Conclusion DM morbidity is significant decreased by drug intervention in patients with IGT, Pioglitazone is superior to other durg in improve insulin sensitivity due to low dose
【Key words】 Impaired glucose tolerance; Diabetes mellitus; Intervention study; Metformin; Acarbose; Pioglitazone;
- 【文献出处】 海南医学 ,Hainan Medical Journal , 编辑部邮箱 ,2007年12期
- 【分类号】R587.1
- 【被引频次】4
- 【下载频次】87